Literature DB >> 15018929

Synthesis and structure-activity relationships of a new model of arylpiperazines. Part 7: Study of the influence of lipophilic factors at the terminal amide fragment on 5-HT(1A) affinity/selectivity.

María L López-Rodríguez1, David Ayala, Alma Viso, Bellinda Benhamú, Roberto Fernández de La Pradilla, Fernando Zarza, José A Ramos.   

Abstract

The influence of lipophilic factors at the amide fragment of a new series of (+/-)-7a-alkyl-2-[4-(4-arylpiperazin-1-yl)butyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazoles 2 and of (+/-)-7a-alkyl-2-[(4-arylpiperazin-1-yl)methyl]-1,3-dioxoperhydropyrrolo[1,2-c]imidazoles 3 has been studied. Variations of logP have been carried out by introducing different hydrocarbonated substituents (R(1)) at the position 7a of the bicyclohydantoin, namely the non-pharmacophoric part. All the new compounds exhibit high potency for the 5-HT(1A) receptor; however, affinities for the alpha(1) receptor are high for compounds 2a-l while compounds 3a-f are selective over this adrenergic receptor. On the other hand, differences in logP do not notably affect the K(i) values for the above receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15018929     DOI: 10.1016/j.bmc.2003.12.006

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.

Authors:  Tony Ngo; Timothy J Nicholas; Junli Chen; Angela M Finch; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-04-27       Impact factor: 3.686

2.  Development of Fluorescent Ligands for the Human 5-HT1A Receptor.

Authors:  Dulce Alonso; Henar Vázquez-Villa; Ana M Gamo; María F Martínez-Esperón; Mariola Tortosa; Alma Viso; Roberto Fernández de la Pradilla; Elena Junquera; Emilio Aicart; Mar Martín-Fontecha; Bellinda Benhamú; María L López-Rodríguez; Silvia Ortega-Gutiérrez
Journal:  ACS Med Chem Lett       Date:  2010-05-14       Impact factor: 4.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.